SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate ...

Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...

Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; ...

SAN DIEGO--(BUSINESS WIRE)--Today, Nextivity – the industry leader in intelligent cellular coverage solutions – announced the expansion of its award-winning CEL-FI product family with the global ...

VIENNA, Va., May 22, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of an ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Almost a quarter century ago today, the Xbox debuted one of its most distinct launch titles — and ...

Tristan Jurkovich began his career as a journalist in 2011. His childhood love of video games and writing fuel his passion for archiving this great medium’s history. He dabbles in every genre, but ...

Crypto lending platform Celsius Network has an approximately $1.2 billion gap in its balance sheet, with most liabilities owed to its users. In addition, the firm has filed for bankruptcy protection, ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...

Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing ...